Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10153)	1/27/2004 11:21:17 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

This why genta makes me nervous. Really, who will be surprised that an assignment can be allowed. The question is whether GSK/genta/successor can prevent or enforce an assignment. Genta Issues Statement Regarding Genasense(TM) Agreement with Aventis Tuesday January 27, 8:06 am ET BERKELEY HEIGHTS, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) issued the following statement in light of recent developments: Genta has in place a commercialization and licensing agreement with Aventis for the Company's lead anticancer product, Genasense(TM) (oblimersen sodium). The agreement contains provisions that allow for assignment to a successor in the event of a change of control of Aventis, such that the terms of the agreement remain unchanged. About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA and DNA-based medicines) .......snip